Abeprazan hydrochloride 是一种钾竞争性酸 (potassium-competitive acid) 阻滞剂。Abeprazan hydrochloride 通过可逆的钾竞争性离子结合抑制 H+，K+- ATPase，而无需酸激活。Abeprazan hydrochloride 是一种潜在的质子泵抑制剂，用于研究与酸相关的疾病。

Abeprazan hydrochloride is a potassium-competitive acid blocker. It inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. It is developed as a potential alternative to a proton pump inhibitor for the treatment of acid-related diseases.

The mechanism of action of Abeprazan hydrochloride is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation[1].

Abeprazan hydrochloride inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion is equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models, and heidenhain pouch dog models[1].

1902954-87-3

C19H18ClF3N2O3S

446.87

DWP14012 hydrochloride;Fexuprazan hydrochloride

DMSO:22.5mg/mL (50.4mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years